

07-18-05

1644

Express Mail No. EV 654 849 984 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Koenig et al.

Serial No.: 10/524,134

Filed: February 11, 2005

For: FCγRIIB SPECIFIC ANTIBODIES AND
METHODS OF USE THEREOF

Confirmation No.: 1503

Art Unit: 1644

Examiner: To be assigned

Attorney Docket No.: 11183-003-999

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 and § 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references A01-A17, B01-B09 and C01-C71 listed on the attached form PTO 1449 entitled "List of References Cited by Applicant." A copy of references B01-B09 and C01-C71 is provided herewith. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. Patents and U.S. Patent Application Publications are not submitted herewith. Also provided herewith is a PCT International Search Report from the counterpart International Application No. PCT/US03/25399.


Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the references be made of record in the file history of the application.

Submission of this Information Disclosure Statement is before the mailing date of the first Office Action on the merits; therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is believed to be due for the filing of this Information Disclosure Statement. Please charge any required fee, including any deficiencies in the amount estimated to be due, to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: July 15, 2005


Margaret B. Brivanlou
JONES DAY
222 East 41st Street
New York, NY 10017-6702
212-326-393940,922
(Reg. No.)

Enclosures

**LIST OF REFERENCES CITED BY APPLICANT**
(Use several sheets if necessary)

ATTY DOCKET NO.

11183-003-999

APPLICATION NO

10/524,134

APPLICANT

Koenig et al.

FILING DATE

February 11, 2005

GROUP

1644

U.S. PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,179,337	12/18/1979	Davis et al.			
	A02	5,711,944	01/27/1998	Gilbert et al.			
	A03	5,888,533	03/30/1999	Dunn			
	A04	5,648,260	07/15/1999	Winter et al.			
	A05	5,945,115	08/31/1999	Dunn et al.			
	A06	6,019,968	02/01/2000	Platz et al.			
	A07	6,132,764	10/17/2000	Li et al.			
	A08	6,194,551	02/27/2001	Idusogie et al.			
	A09	6,218,149	04/17/2001	Morrison et al.			
	A10	2001/0036459	11/01/2001	Ravetch			
	A11	6,339,069	01/15/2002	Meers et al.			
	A12	2002/0028486	03/07/2002	Morrison et al.			
	A13	6,420,149	07/16/2002	Fukuda et al.			
	A14	6,472,511	10/29/2002	Leung et al.			
	A15	6,528,624	03/04/2003	Idusogie et al.			
	A16	2003/0115614	06/19/2003	Kanda et al.			
	A17	5,837,243	11/17/1997	Deo et al.			

FOREIGN PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	B01	WO 94/18330 A1	08/18/1994	PCT			
	B02	WO 99/58572 A1	11/18/1999	PCT			
	B03	WO 00/42072 A1	07/20/2000	PCT			
	B04	WO 01/79299 A1	10/25/2001	PCT			
	B05	WO 03/035835 A2	05/01/2003	PCT			
	B06	WO 03/066095 A2	08/14/2003	PCT			
	B07	EP 0 359 096 B1	11/05/1997	EPC			
	B08	EP 1 006 183 A1	06/07/2000	EPC			
	B09	EP 0 343 950 B1	10/18/2000	EPC			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Abra et al., The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res. 2002 Feb-May;12(1-2):1-3
	C02	Bendas G, Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs. 2001;15(4):215-24.
	C03	Billadeau et al., ITAMs versus ITIMs: striking a balance during cell regulation, J Clin Invest. 2002 Jan;109(2):161-8

C04	Bolland and Ravetch., Inhibitory pathways triggered by ITIM-containing receptors. <i>Adv Immunol.</i> 1999;72:149-177
C05	Bolland et al., Genetic modifiers of systemic lupus erythematosus in FcγRIIB(-/-) mice. <i>J Exp Med.</i> 2002 May 6;195(9):1167-74
C06	Boruchov et al., Expression and modulation of the inhibitory Fcγ receptor, FcγRIIb (CD32b), on human dendritic cells (DCs). Laboratory of Cellular Immunobiology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY, NY 10021
C07	Brauweiler et al., Partially distinct molecular mechanisms mediate inhibitory FcγRIIB signaling in resting and activated B cells. <i>J Immunol.</i> 2001;167:204-211
C08	Brown EJ., In vitro assays of phagocytic function of human peripheral blood leukocytes: receptor modulation and signal transduction. <i>Methods Cell Biol.</i> 1994;45:147-164
C09	Budde et al., Specificity of CD32 mAb for FcγRIIa, FcγRIIb1, and FcγRIIb2 expressed in transfected mouse B cells and BHK-21 cells. <i>Leukocyte Typing V: White cell differentiation antigens.</i> 1995;828-832 (Schlossman, Boumsell, Gilks, Harlan, Kishimoto, eds.)
C10	Callanan et al., The IgG Fc Receptor, FcγRIIB is a target for deregulation by chromosomal translocation in malignant lymphoma. <i>PNAS.</i> 2000 Jan;97(1):309-314.
C11	Cameron et al., Differentiation of the human monocyte cell line, U937, with dibutyryl cyclicAMP induces the expression of the inhibitory Fc receptor, FcγRIIb. <i>Immunol Lett.</i> 2002 Oct 1;83(3):171-9
C12	Camilleri-Broët et al., FcγRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. <i>Br J Haematol.</i> 2004;124(1):55-62
C13	Cassard et al., Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells. <i>The J Clin Invest.</i> 2002 November;110(10):1549-1557
C14	Chappel et al., Identification of the FCγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. <i>Proc. Natl. Acad. Sci. USA.</i> 1991 October;88(20):9036-9040
C15	Clynes et al., Inhibitory Fc receptors modulate <i>in vivo</i> cytotoxicity against tumor targets. <i>Nat Med</i> 2000;6(4):443-6
C16	Damle et al., B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. <i>Blood</i> 2002 June 1;99(11):4087-4093
C17	Davies et al., Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγ RIIB. <i>Biotechnol Bioeng.</i> 2001 Aug 20;74(4):288-94
C18	Daëron et al., The Same Tyrosine Based Inhibition Motif, in the Intracytoplasmic Domain of FcγRIIB, regulates negatively BCR, TCR- and FcR dependent cell activation. <i>Immunity.</i> 1995 Nov;3: 635-646
C19	Ding et al., Inhibition of the function of the FcγRIIB by a monoclonal antibody to thymic shared antigen-1, a Ly-6 family antigen. <i>Immunology.</i> 2001 Sep;104(1):28-36
C20	Eppstein et al., Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor. <i>Proc Natl Acad Sci U S A.</i> 1985 Jun;82(11):3688-92
C21	Fanger et al., Production and use of anti-FcR bispecific antibodies. <i>Immunomethods.</i> 1994 Feb;4(1):72-81
C22	Farag, et al., FcγRIIIa and FcγRIIIa polymorphisms do not predict response to Rituximab in B-cell chronic lymphocytic leukemia. <i>Blood.</i> 2003 Oct 16 (15 pp.)
C23	Fidler, I. J., Macrophages and metastasis--a biological approach to cancer therapy. <i>Cancer Res.</i> 1985 Oct;45(10):4714-26.
C24	Gerber et al., Stimulatory and inhibitory signals originating from the macrophage Fcγ receptors. <i>Microbes Infect.</i> 2001 Feb;3(2):131-9
C25	Holmes et al., Alleles of the Ly-17 alloantigen define polymorphisms of the murine IgG Fc receptor. <i>Proc Natl Acad Sci USA.</i> 1985 Nov;82(22):7706-10
C26	Hwang et al., Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study. <i>Proc Natl Acad Sci U S A.</i> 1980 Jul;77(7):4030-4
C27	Isaacs et al., Therapy with monoclonal antibodies. II. The contribution of Fcγ receptor binding and the influence of CH1 and CH3 domains on <i>in vivo</i> effector function. <i>The Journal of Immunology.</i> 1998;161:3862-3869
C28	Jefferis et al., Recognition sites on human IgG for Fcγ receptors: the role of glycosylation. <i>Immunol Lett.</i> 1995 Jan;44(2-3):111-7
C29	Kagari et al., Essential Role of Fcγ Receptors in anti-type II collagen antibody induced arthritis. <i>J. Immunol.</i> Apr. 2003;170:4318-24
C30	Lifely et al., Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. <i>Glycobiology.</i> 1995 Dec;5(8):813-22
C31	Lin et al., Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. <i>J Exp Med.</i> 2001;193(6):727-739.
C32	Lin et al., The macrophage growth factor CSF-1 in mammary gland development and tumor progression. <i>J Mammary Gland Biol Neoplasia.</i> 2002;7(2):147-62
C33	Lyden et al., The Fc receptor for IgG expressed in the villus endothelium of human placenta is Fcγ RIIB2. <i>J Immunol.</i> 2001 Mar 15;166(6):3882-9
C34	Malbec et al., Fcε receptor I-associated <i>lyn</i> -dependent phosphorylation of Fcγ receptor IIB during negative regulation of mast cell activation. <i>J Immunol.</i> 1998 Feb 15;160(4):1647-58
C35	Maruyama K, <i>In vivo</i> targeting by liposomes. <i>Biol Pharm Bull.</i> 2000 Jul;23(7):791-9

C36	Metcalfe, Mast Cells. <i>Physiol Rev.</i> 1997 Oct;77(4):1033-79
C37	Micklem et al., Different isoforms of human FcRII distinguished by CDw32 antibodies. <i>J Immunol.</i> 1990 March;144:2295-2303
C38	Nakamura et al., Fcγ receptor IIB-deficient mice develop Goodpasture's Syndrome upon immunization with Type IV collagen: a novel murine model for Autoimmune Glomerular Basement Membrane Disease. <i>J. Exp. Med.</i> 2000 March 6;191(5):899-905
C39	Norris et al., A naturally occurring mutation in FcγRIIA: A Q to K ¹²⁷ change confers unique IgG binding properties to the R ¹³¹ allelic form of the receptor. <i>Blood.</i> 1998 January 15;91(2):656-662
C40	Ott et al., Downstream of Kinase, p62 ^{dok} , Is a mediator of FcγRIIB inhibition of FcεRI signaling. <i>J. of Immunol.</i> 2002;168:4430-9
C41	Park et al., Immunoliposomes for cancer treatment. <i>Adv Pharmacol.</i> 1997;40:399-435
C42	Park YS, Tumor-directed targeting of liposomes. <i>Biosci Rep.</i> 2002 Apr;22(2):267-81
C43	Presta LG, Engineering antibodies for therapy. <i>Curr Pharm Biotechnol.</i> 2002 Sep;3(3):237-56
C44	Pricop et al., Differential modulation of stimulatory and inhibitory Fcγ receptors on human monocytes by Th1 and Th2 cytokines. <i>J Immunol.</i> 2001 Jan 1;166(1):531-7
C45	Pulford et al., A new monoclonal antibody (KB61) recognizing a novel antigen which is selectively expressed on a subpopulation of human B lymphocytes. <i>Immunology.</i> 1986 Jan;57(1):71-6
C46	Qin et al., Fcγ receptor IIB on follicular dendritic cells regulates the B cell recall response. <i>J Immunol.</i> 2000;164:6268-6275
C47	Ravetch and Bolland, IgG Fc receptors. <i>Annu Rev Immunol.</i> 2001;19:275-290
C48	Ravetch et al., Fc Receptors. <i>Annu Rev Immunol.</i> 1991;9:457-92
C49	Ravetch et al., Fc receptors: rubor redux. <i>Cell.</i> 1994 Aug 26;78(4):553-60
C50	Ravetch et al., Immune inhibitory receptors. <i>Science.</i> 2000 Oct 6;290(5489):84-9.
C51	Real et al., IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. <i>Cancer Res.</i> 2001;61(14): 5517-22
C52	Routledge et al., The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. <i>Transplantation.</i> 1995 Oct 27;60(8):847-53
C53	Samuelsson et al., Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. <i>Science.</i> 2001 January 19; 291:484-486
C54	Sarkar et al., Negative signaling via FcγRIIB1 in B cells blocks phospholipase Cγ2 tyrosine phosphorylation but not Syk or Lyn activation. <i>J Biol Chem.</i> 1996 Aug 16;271(33):20182-6
C55	Scholl et al., Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis? <i>Mol Carcinog.</i> 7(4):207-11
C56	Shields et al., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγ RIII and antibody-dependent cellular toxicity. <i>J Biol Chem.</i> 2002 Jul 26;277(30):26733-40
C57	Sondermann et al., The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. <i>Nature.</i> 2000 Jul 20;406(6793):267-273
C58	Tam et al., A bispecific antibody against human IgE and human FcγRII that inhibits antigen-induced histamine release by human mast cells and basophils. <i>Allergy</i> 2004;59:772-780
C59	Tao and Morrison, Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. <i>J Immunol.</i> 1989 Oct 15;143(8):2595-601
C60	Todorovska et al., Design and application of diabodies, triabodies and tetrabodies for cancer targeting. <i>J Immunol Methods.</i> 2001 Feb 1;248(1-2):47-66
C61	Tridandapani et al., Regulated Expression and Inhibitory Function of FcγRIIb in Human Monocytic Cells, <i>Journal of Biol. Chem.</i> 277(7):50582-9
C62	Umaña et al., Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. <i>Nat Biotechnol.</i> 1999 Feb;17(2):176-80
C63	Van Nguyen et al., Colony stimulating factor-1 is required to recruit macrophages into the mammary gland to facilitate mammary ductal outgrowth. <i>Dev Biol.</i> 2002;247(1):11-25
C64	Van Sorge et al., FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. <i>Tissue Antigens.</i> 2003;61:189-202
C65	Vingerhoeds et al., Immunoliposomes in vivo. <i>Immunomethods.</i> 1994 Jun;4(3):259-72
C66	Wallick et al., Glycosylation of a VH residue of a monoclonal antibody against α (1→6) dextran increases its affinity for antigen. <i>J Exp Med.</i> 1988 Sep 1;168(3):1099-109
C67	Warmerdam et al., Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). <i>J Exp Med.</i> 1990 Jul 1;172(1):19-25
C68	Weinrich et al., Epitope mapping of new monoclonal antibodies recognizing distinct human FcRII (CD32) isoforms. <i>Hybridoma</i> 1996 Nov 2; 15:109-116
C69	Wright and Morrison, Effect of glycosylation on antibody function: implications for genetic engineering. <i>Trends Biotechnol.</i> 1997 Jan;15(1):26-32
C70	Xu et al., FcγRs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody Based Therapeutics. <i>J Immunol.</i> 2003;171:562-68

	C71	Xu et al., Residue at position 331 in the IgG1 and IgG4 C _H 2 domains contributes to their differential ability to bind and activate complement. The Journal of Biological Chemistry, 1994 Feb 4;269(5):3469-3474
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		